CHDI makes biosamples available to the HD research community to facilitate a broad variety of HD research and accelerate progress towards the development of therapeutics that will benefit HD-affected individuals. To date, CHDI has distributed over 46,000 biosamples for HD research. Biosamples collected from research participants are stored and made available to any interested researcher working at a recognized research institution through a simple verification process.
CHDI maintains a repository of renewable (lymphoblastoid cell lines [LBCL] and DNA from cell lines) and non-renewable (serum, cerebrospinal fluid, plasma, lymphocytes, DNA from whole blood, cells from CSF, RNA from whole blood, and buccal swabs) biosamples. The table provides information about CHDI’s biorepository collection broken down by clinical study and biosample type.
CHDI has a straightforward biosample application process; any verified researcher may request biosamples from the studies listed below. Complete a Biosample Request Form with a detailed project description and type and volume of biosamples requested. Further study committee approval is required to release non-renewable biosamples:
- Enroll-HD – biosamples are available for a baseline visit and for up to 11 follow-up visits
- Registry – biosamples are available for a baseline visit and for up to 11 follow-up visits
- TRACK-HD/Track-On HD – data from baseline visit up to four follow-up visits for each research participant
- Mito-HD – contact email@example.com
Biosamples are stored at -80⁰C in freezers and -180⁰C in liquid nitrogen vapor. Depending on the type of biosample, they are stored/shipped in 2ml cryovials, 2D barcoded matrix tubes, glass ampoules, and/or ACD tubes. Any volume and/or concentration can be requested.
Biosamples are provided subject to a nominal shipping and handling fee that covers the actual shipping fee. This fee is based upon the type of renewable or non-renewable biosamples, number of biosamples, volume, concentration ordered, and shipment address provided. CHDI has substantial material costs associated with the collection, processing, storage and distribution of biosamples, and our stance is that academic and industrial investigators wanting to use the biosamples should bear some of those costs and factor them into their funding applications.